Resmed Inc Bottom Line Rises In Q3

Resmed reported third-quarter GAAP earnings of $398.7 million, or $2.74 per share, up from $365.0 million, or $2.48 per share, a year earlier. Revenue rose 10.8% to $1.431 billion from $1.291 billion, while adjusted EPS came in at $2.86. The results indicate solid top- and bottom-line growth for the sleep apnea and respiratory care company.

Analysis

The key read-through is that demand appears healthy enough to support continued operating leverage, but the more important signal is resilience in a category that is often treated as slow-growth. If this cadence persists, the market may need to re-rate the stock less as a mature med-tech name and more as a durable recurring-revenue platform with secular patient-acquisition and replacement-cycle tailwinds. That can matter for multiples because steady mid-teens earnings growth with low cyclicality tends to command a premium only after a few quarters of confirmation.

Second-order winners are the distribution and service layers around sleep apnea care, while slower-moving competitors may find it harder to win share if the category leader is growing without obvious price pressure. The risk is that this strength invites capacity expansion and more aggressive channel inventory by competitors, which can compress future gross margin before it shows up in top-line data. In other words, the next leg of the story is not revenue; it is whether incremental growth is bought with mix deterioration or SG&A creep.

Near term, the stock likely trades well on the print, but the more interesting horizon is 3-6 months, when investors test whether this is a one-off beat or a durable step-up in demand. The main reversal catalysts are reimbursement friction, FX headwinds, and any evidence that growth is being pulled forward rather than structurally improved. If the market extrapolates too aggressively, the risk/reward shifts from fundamental upside to multiple risk.

Consensus may be underappreciating how defensible the earnings stream becomes when recurring consumables and replacement demand accelerate at the same time as patient starts. That combination can create an earnings surprise loop: stronger installed base leads to better conversion on consumables, which then supports better pricing power and less volatile margins. The contrarian bear case is not that growth stops, but that the market pays for permanence before it is fully proven.

Key Decisions for Investors

• Long RMD on 1-3 month horizon into post-earnings follow-through; prefer pullbacks over chasing the opening gap, with upside driven by multiple expansion if management confirms sustained demand.
• Buy RMD call spreads 2-4 months out to express upside with defined downside; best if implied volatility remains elevated after the print.
• Pair trade: long RMD vs short a lower-quality medtech/consumables peer basket over 3-6 months to capture relative re-rating if this print proves the category is structurally accelerating.
• Set a risk trigger on RMD if management commentary signals reimbursement or margin pressure; the trade works until investors start pricing in growth at the expense of future gross margin.